ASH19: Johnson & Johnson's BCMA-directed CAR-T therapy JNJ-4528 shows 100% response rate in multiple myeloma study

Press/Media

Period	8 Dec 2019

Media coverage

Title	ASH19: Johnson & Johnson's BCMA-directed CAR-T therapy JNJ-4528 shows 100% response rate in multiple myeloma study
Media name/outlet	FirstWord Pharma
Country/Territory	United States
Date	8/12/19
URL	www.firstwordpharma.com/node/1686231?tsid=1
Persons	Deepu Madduri